Diabetes drug tested in Parkinson's disease patients

May 20, 2013, Journal of Clinical Investigation

Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease.

In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in . PD patients were divided into two groups: 20 patients received Exenatide injections for 12 months, while the other group of 24 patients served as controls.

Due to high manufacturing costs, the control group did not receive placebo injections and the patients were aware of their group assignment. Foltynie and colleagues observed that Exenatide was well tolerated. After one year of treatment patients receiving Exenatide displayed improved cognitive ability and motor skills, while control patients declined.

Though this trial cannot rule out a , the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD.

In the accompanying commentary, Roger Barker (University of Cambridge), Mark Stacy (Duke University) and Patrik Brundin (Van Andel Institute) discuss the novel, cost-saving clinical trial design used in this study.

Explore further: Head-to-head trial of two diabetes drugs yields mixed results

More information: Exenatide and the treatment of patients with Parkinson's disease, J Clin Invest. doi:10.1172/JCI68295
A new approach to disease-modifying drug trials in Parkinson's disease, J Clin Invest. doi:10.1172/JCI69690

Related Stories

Head-to-head trial of two diabetes drugs yields mixed results

November 6, 2012
A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

Study suggests glucagon-like peptide-1 receptor agonists related to adolescent weight loss

February 4, 2013
Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according ...

Mild cognitive impairment at Parkinson's disease diagnosis linked with higher risk for early dementia

March 25, 2013
Mild cognitive impairment at the time of Parkinson disease (PD) diagnosis appears to be associated with an increased risk for early dementia in a Norwegian study, according to a report published Online First by JAMA Neurology.

Innovative new strategy to treat Parkinson's disease

December 19, 2011
Stabilizing the cell's power-generating center protects against Parkinson's disease (PD) in a rat model, according to a report published online this week in the Journal of Experimental Medicine.

Blood-based biomarkers may lead to earlier diagnosis of Parkinson's disease

January 21, 2013
Parkinson's disease (PD) is a progressive neurological condition. At present, it is usually diagnosed only when motor features are present. Hence, there is a need to develop objective and measurable biomarkers to improve ...

Recommended for you

Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients ...

New brainstem changes identified in Parkinson's disease

January 4, 2018
A pioneering study has found that patients with Parkinson's disease have more errors in the mitochondrial DNA within the brainstem, leading to increased cell death in that area.

Caffeine level in blood may help diagnose people with Parkinson's disease

January 3, 2018
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson's disease, according to a study published in the January 3, 2018, online issue of Neurology, the medical journal of the ...

Researchers shed light on why exercise slows progression of Parkinson's disease

December 22, 2017
While vigorous exercise on a treadmill has been shown to slow the progression of Parkinson's disease in patients, the molecular reasons behind it have remained a mystery.

Robotic device improves balance and gait in Parkinson's disease patients

December 19, 2017
Some 50,000 people in the U.S. are diagnosed with Parkinson's disease (PD) every year. The American Institute of Neurology estimates there are one million people affected with this neurodegenerative disorder, with 60 years ...

New findings point to potential therapy for Parkinson's Disease

December 19, 2017
A new study, published in Proceedings of the National Academy of Sciences (PNAS), sheds light on a mechanism underlying Parkinson's disease and suggests that Tacrolimus—an existing drug that targets the toxic protein interaction ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.